FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200341631> ?p ?o ?g. }

• W4200341631 endingPage "S720" @default.
• W4200341631 startingPage "S720" @default.
• W4200341631 abstract "Abstract Background Avibactam (AVI) is a β-lactamase inhibitor with potent inhibitory activity against Class A, Class C, and some Class D serine β-lactamases. The combination of ceftazidime (CAZ) with AVI has been approved in Europe and in the United States for several indications. This study evaluated the in vitro activity of CAZ-AVI and comparators against Enterobacterales (Eba) and Pseudomonas aeruginosa (Pae) isolates collected from patients with bloodstream infections as part of the ATLAS surveillance program in 2017-2019. Methods A total of 48193 Eba and 15376 Pae non-duplicate clinically significant isolates, including 9224 Eba and 1808 Pae isolated from bloodstream infections, were collected in 53 countries in Europe, Latin America, Asia/Pacific (excluding mainland China), and the Middle East/Africa region. Susceptibility testing was performed by CLSI broth microdilution. CAZ-AVI was tested at a fixed concentration of 4 µg/ml AVI. Meropenem-nonsusceptible (MEM-NS) Eba and Pae isolates were screened for the presence of β-lactamase genes. Results Susceptibility data are shown in the Table. Percentages of susceptibility (% S) to the tested agents were 0.4-3.4% lower among Eba and Pae from bloodstream infections compared to isolates from combined sources in most cases. CAZ-AVI showed potent in vitro activity against all Eba bloodstream isolates and the CAZ-NS subset (MIC90, 0.5-4 µg/ml, 91.7-97.4% S). Reduced activity against MEM-NS Eba was attributable to carriage of class B metallo-β-lactamases (MBLs) as 98.1% of MEM-NS MBL-negative isolates were susceptible to CAZ-AVI. None of the tested comparators exceeded the activity of CAZ-AVI. CAZ-AVI also showed good in vitro activity against the majority of Pae bloodstream isolates (MIC90, 16 µg/ml, 89.7% S). Activity was reduced against CAZ-NS and MEM-NS subsets (55.9-63.0% S), which included isolates carrying MBLs, but exceeded the activity of CAZ against MEM-NS and MEM against CAZ-NS by 26-28 percentage points. Amikacin was the only tested comparator that demonstrated comparable activity against Pae bloodstream isolates. Results Table Conclusion CAZ-AVI provides a valuable therapeutic option for treating bloodstream infections caused by MBL-negative Eba and Pae isolates. Disclosures Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Meredith Hackel, PhD MPH, IHMA (Employee)Pfizer, Inc. (Independent Contractor) Gregory Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Independent Contractor)" @default.
• W4200341631 created "2021-12-31" @default.
• W4200341631 creator A5017159626 @default.
• W4200341631 creator A5020290756 @default.
• W4200341631 creator A5020992600 @default.
• W4200341631 creator A5038009031 @default.
• W4200341631 date "2021-11-01" @default.
• W4200341631 modified "2023-09-23" @default.
• W4200341631 title "1263. In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2017-2019" @default.
• W4200341631 doi "https://doi.org/10.1093/ofid/ofab466.1455" @default.
• W4200341631 hasPublicationYear "2021" @default.
• W4200341631 type Work @default.
• W4200341631 citedByCount "0" @default.
• W4200341631 crossrefType "journal-article" @default.
• W4200341631 hasAuthorship W4200341631A5017159626 @default.
• W4200341631 hasAuthorship W4200341631A5020290756 @default.
• W4200341631 hasAuthorship W4200341631A5020992600 @default.
• W4200341631 hasAuthorship W4200341631A5038009031 @default.
• W4200341631 hasBestOaLocation W42003416311 @default.
• W4200341631 hasConcept C176947019 @default.
• W4200341631 hasConcept C2775933652 @default.
• W4200341631 hasConcept C2776968632 @default.
• W4200341631 hasConcept C2777406300 @default.
• W4200341631 hasConcept C2777637488 @default.
• W4200341631 hasConcept C2780950330 @default.
• W4200341631 hasConcept C501593827 @default.
• W4200341631 hasConcept C523546767 @default.
• W4200341631 hasConcept C54355233 @default.
• W4200341631 hasConcept C71924100 @default.
• W4200341631 hasConcept C86803240 @default.
• W4200341631 hasConcept C89423630 @default.
• W4200341631 hasConceptScore W4200341631C176947019 @default.
• W4200341631 hasConceptScore W4200341631C2775933652 @default.
• W4200341631 hasConceptScore W4200341631C2776968632 @default.
• W4200341631 hasConceptScore W4200341631C2777406300 @default.
• W4200341631 hasConceptScore W4200341631C2777637488 @default.
• W4200341631 hasConceptScore W4200341631C2780950330 @default.
• W4200341631 hasConceptScore W4200341631C501593827 @default.
• W4200341631 hasConceptScore W4200341631C523546767 @default.
• W4200341631 hasConceptScore W4200341631C54355233 @default.
• W4200341631 hasConceptScore W4200341631C71924100 @default.
• W4200341631 hasConceptScore W4200341631C86803240 @default.
• W4200341631 hasConceptScore W4200341631C89423630 @default.
• W4200341631 hasIssue "Supplement_1" @default.
• W4200341631 hasLocation W42003416311 @default.
• W4200341631 hasLocation W42003416312 @default.
• W4200341631 hasOpenAccess W4200341631 @default.
• W4200341631 hasPrimaryLocation W42003416311 @default.
• W4200341631 hasRelatedWork W1524642279 @default.
• W4200341631 hasRelatedWork W2261913017 @default.
• W4200341631 hasRelatedWork W2901057130 @default.
• W4200341631 hasRelatedWork W2946700181 @default.
• W4200341631 hasRelatedWork W3027419335 @default.
• W4200341631 hasRelatedWork W3119311612 @default.
• W4200341631 hasRelatedWork W4224302300 @default.
• W4200341631 hasRelatedWork W4310676567 @default.
• W4200341631 hasRelatedWork W4319295365 @default.
• W4200341631 hasRelatedWork W4321189322 @default.
• W4200341631 hasVolume "8" @default.
• W4200341631 isParatext "false" @default.
• W4200341631 isRetracted "false" @default.
• W4200341631 workType "article" @default.